Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Positive Phase III ENCORE for Genzyme's eliglustat in Gaucher's

This article was originally published in Scrip

Executive Summary

Prospects for Genzyme's oral Gaucher disease therapy eliglustat tartrate strengthened on 15 February when the Sanofi-owned company reported positive topline data from the Phase III ENCORE clinical trial on the same day investigators presented detailed results from the Phase III ENGAGE trial at the Lysosomal Disease Network (LDN) WORLD Symposium in Orlando, Florida.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC020410

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel